Randomized, Controlled Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali.

Trial Profile

Randomized, Controlled Phase 2 Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs AS02 (Primary) ; Malaria vaccine (Primary) ; Rabies vaccine
  • Indications Falciparum malaria; Rabies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 14 Oct 2011 Additional lead trial center identified as reported by ClinicalTrials.gov.
    • 15 Sep 2011 Primary endpoint 'Infection-rate' has not been met (3060803).
    • 15 Sep 2011 Results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top